Aequus Pharmaceuticals (CVE:AQS) Hits New 1-Year Low – Here’s What Happened

by · The Cerbat Gem

Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during trading on Monday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 29000 shares changing hands. The stock had previously closed at C$0.02.

Aequus Pharmaceuticals Stock Performance

The company’s fifty day moving average price is C$0.01 and its 200 day moving average price is C$0.02. The company has a market cap of C$1.33 million, a PE ratio of -1.00 and a beta of -0.02. The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46.

Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last posted its quarterly earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share for the quarter. The company had revenue of C$0.16 million for the quarter. On average, equities research analysts predict that Aequus Pharmaceuticals Inc. will post -0.1 earnings per share for the current year.

Aequus Pharmaceuticals Company Profile

(Get Free Report)

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.

See Also